drugset / Trial / NCT00776230
Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling
Non-randomizedSingle-groupOpen-labelPrevention
Summary
The objective is to assess immunogenicity of a commercial IC51 batch at 3 different time points post filling (12, 18, 24 months) in terms of Geometric Mean Titers (GMT) for anti-JEV neutralizing antibodies at Day 56 after the first vaccination.
Timeline
- Start
- 2008-09
- Primary completion
- 2010-06
- Completion
- 2010-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | IC51 | Vaccine | 6 ug | Intramuscular |